



# TM STONEHAGE FLEMING

PREVIOUSLY KNOWN AS TM CAVENDISH AIM FUND





l



LONG-TERM INVESTMENT HORIZONS





NAVIGATING TO INVESTMENTS WITH CLEAR STRATEGIES

# KEY FACTS

| Launch Date       | 5 October 2005       |
|-------------------|----------------------|
| IA Sector         | UK Smaller Companies |
| Fund Size         | £77.5m               |
| Dealing Frequency | Daily                |

### FEES

| Initial Charge           | Up to 5.00% |
|--------------------------|-------------|
| Ongoing Charges          | 0.69%       |
| Annual Management Charge | 0.60%       |

# MINIMUM INVESTMENT

| Lump Sum        | £50,000 |
|-----------------|---------|
| Additional      | £5,000  |
| Regular Savings | N/A     |

PAUL MUMFORD

# PORTFOLIO MANAGER



#### Paul Mumford has extensive investment experience. Having worked initially as an Analyst for Norris Oakley Brothers and later as a smaller companies expert at R Nivison, he moved to fund management in 1988 when he

joined Glenfriars. He then joined Cavendish Asset Management at the group's formation in 1994. The acquisition of Cavendish Asset Management was made by Stonehage Fleming in July 2020. Paul is the co-manager of the TM Stonehage Fleming Aim Fund and the TM Stonehage Fleming Opportunities Fund.



# NICK BURCHETT

Nick Burchett began his career in 1983 at Strauss Turnbull and subsequently joined W.I. Carr in 1990 which later became Investec Wealth & Investment after a number of mergers and acquisitions. During this period Nick dealt

extensively with Paul Mumford on the analysis of UK equities, markets and execution factors. This partnership made a compelling proposition and after 27 years at Investec he joined Cavendish Asset Management in November 2017 to jointly manage the funds. The acquisition of Cavendish Asset Management was made by Stonehage Fleming in July 2020. Nick is the co-manager of the TM Stonehage Fleming Aim Fund and the TM Stonehage Fleming Opportunities Fund.

#### AWARDS





The Fund aims to invest mainly in equities on the UK Alternative Investment Market ('AIM'). This will be achieved by an actively managed diversified portfolio of shares spread across any sector of AIM. In addition, the Fund may on occasion invest in fully listed shares of companies with smaller market capitalisations.

# PORTFOLIO PERFORMANCE



#### STANDARDISED FUND PERFORMANCE (%)

| Performance             | 3m  | 6m   | YTD  | lyr  | 3yrs | 5yrs  |
|-------------------------|-----|------|------|------|------|-------|
| TM SF AIM B             | 8.9 | 35.9 | -8.4 | -0.7 | 21.9 | 104.8 |
| Numis Alt Markets Index | 8.5 | 39.6 | -0.5 | 10.1 | -0.7 | 43.7  |
| Peer Group Percentile   | 18  | 14   | 34   | 54   | 11   | 1     |

# DISCRETE 12 MONTH PERFORMANCE (%)

| 12 months to 30 September | 2020 | 2019  | 2018 | 2017 | 2016 |
|---------------------------|------|-------|------|------|------|
| TM SF AIM B               | -0.7 | 6.7   | 15.0 | 41.0 | 19.1 |
| Numis Alt Markets Index   | 10.1 | -17.5 | 9.3  | 24.8 | 15.9 |
| Peer Group Percentile     | 54   | 1     | 21   | 5    | 5    |

#### CALENDAR YEAR PERFORMANCE (%)

| Performance             | YTD  | 2019 | 2018  | 2017 | 2016 | 2015 |
|-------------------------|------|------|-------|------|------|------|
| TM SF AIM B             | -8.4 | 36.7 | -7.2  | 32.8 | 31.4 | 7.4  |
| Numis Alt Markets Index | -0.5 | 14.7 | -17.5 | 27.4 | 16.2 | 5.6  |

Source: Morningstar, % growth, total return, GBP, single price, UK net income reinvested with no initial charges.

# PERFORMANCE DISCLOSURE

Past performance is not a guide to future performance. The value of investments can fall. Investors may not get back the amount invested. Income from investments may vary and is not guaranteed. For a full list of risks applicable to this fund, please refer to the Prospectus. If the information is not displayed in your base currency, then the return may increase or decrease due to currency fluctuations. Source for all performance is Stonehage Fleming Investment Management Limited as at 30 September 2020. Total return (with dividends) is net of fees.





Health Care

Industrials

Energy

Information Technology

Communication Services

Consumer Discretionary

**Consumer Staples** 

Materials

Real Estate

Financials

# TM STONEHAGE FLEMING AIM FUND

PREVIOUSLY KNOWN AS TM CAVENDISH AIM FUND

#### **RISK ANALYSIS**

| Alpha                                   | 7.38       | based on 3 years' worth                         |  |  |  |
|---|------------|---|--|--|--|
| Beta                                    | 0.98       | of monthly data points.<br>Source: Morningstar, |  |  |  |
| R-Squared                               | 0.80       | relative statistics<br>calculated over 3        |  |  |  |
| Standard Deviation                      | 23.87      | years using the Numis<br>Alternative Markets    |  |  |  |
| Sharpe Ratio                            | 0.37       | Index, total return as at 30/09/2020.           |  |  |  |
|   |            |   |  |  |  |
| ENQUIRIES AND                           | D DEAL     | .ING  |  |  |  |
| 0333 300 0355                           |            |   |  |  |  |
| (press 1 for Enquiries                  | s, press 2 | for Dealing)                                    |  |  |  |
| DEALING:                                |            |   |  |  |  |
| Tutman LLP, PO Box 3733,                |            |   |  |  |  |
| Royal Wootton Bassett, Swindon, SN4 4BG |            |   |  |  |  |
| SEDOL CODES:                            |            |   |  |  |  |
| Class B Share                           |            | B0JX3Z5   |  |  |  |
| ISIN CODES:                             |            |   |  |  |  |
| Class B Share                           |            | GB00B0JX3Z52                                    |  |  |  |
| LIPPER IDS:                             |            |   |  |  |  |
| Class B Share                           |            | 65009655  |  |  |  |

#### SECTOR ALLOCATION (%)

# TOP TEN HOLDINGS (%)

| 24.1 | Venture Life Group Plc        | 4.6 |
|------|-------------------------------|-----|
| 23.0 | Eagle Eye Solutions Group Plc | 3.5 |
| 22.4 | EKF Diagnostics Holdings Plc  | 3.3 |
| 5.7  | Totally Plc                   | 3.0 |
| 5.3  | Beximco Pharmaceuticals       | 2.5 |
| 4.6  | Yourgene Health Plc           | 2.4 |
| 4.6  | Natcall                       | 2.2 |
| 4.2  | Bango Plc                     | 2.1 |
| 1.7  | Independent Oil & Gas Plc     | 2.1 |
| 1.2  | Tristel Plc                   | 2.0 |

Source: Tutman LLP and Stonehage Fleming Investment Management Limited as at 30 September 2020. Third parties whose data may be included in this document do not accept any liability for errors or omissions

#### PORTFOLIO COMMENTARY

The TM Stonehage Fleming AIM Fund returned -3.3% during September. A feature of the month was the strong performance of some of the largest companies listed on AIM, and as the TM Stonehage Fleming AIM Fund does not have a significant exposure here, it lagged the Numis Alternative Markets Index, which returned -0.3%.

Ex-Post Risk calculations are

We added to several holdings and started new holdings in two companies where we had taken profits earlier in the year. Fortunately, we were able to acquire an interest in EMIS at a very attractive level. The company specializes in software used by GPs for patient records and has a sound record of growth and a strong balance sheet. The other new holding was in Centralnic, the specialist company in the domain name market place, which raised money to make an earnings enhancing acquisition. There were no material sales, and we were able to reinvest funds arising from receipt of the cash arising from the takeover of our holding in RockRose.

#### IMPORTANT INFORMATION

Derivatives have not been used but are allowed if appropriate for efficient asset management. The Fund only invests in UK assets but is allowed to hold shares on overseas exchanges. This would occur in the event of a company delisting from the London stock market and would not expected to be material. Hence, there would be limited foreign exchange risk.

The fund invests in AIM listed companies, which can carry a higher risk of failure and be less liquid than shares listed on other exchanges. These may experience greater price movements and wider spreads (difference between the buying and selling prices) which could affect the value of the fund.

Stonehage Fleming Investment Management Limited, which is authored Financial Conduct Authority (reference number 194382), is the appointed investment manager of the TM Stonehage Fleming Investments Funds. This fund is a UCITS sub-fund of the TM Stonehage Fleming Investments Funds. The TM Stonehage Fleming Investments Funds is an Open Ended Investment Company (OEIC) incorporated under the OEIC Regulations. The company is incorporated in England & Wales with registered number IC000195. It is a UCITS scheme as defined in COLL and is an umbrella company, for the purposes of the OEIC Regulations. It is authorised and regulated in the UK by the Financial Conduct Authority (reference number 407782).

The UK stock market is still well below its peak level, with investors looking for growth in overseas markets. The COVID-19 situation has also prompted many companies to pass or defer dividend payments, which has put pressure on share prices, with income funds being forced to sell. With smaller companies, management can be much more flexible and many have discovered activities which can take advantage of the background situation. The TM Stonehage Fleming AIM Fund has good exposure to the IT and healthcare sectors of the stock market where significant opportunities exist. It also contains potential from its holding in the oil and gas sector where considerable value can be found. A majority of company management that we have met are optimistic about longer term prospects, but we would be careful to avoid those areas where the COVID-19 pandemic would have a long-lasting negative impact. BREXIT is also an area of uncertainty, but, to some extent, this is discounted in the current level of the UK stock market, and we think that the TM Stonehage Fleming AIM Fund is well positioned moving forward.

The Authorised Corporate Director ("ACD") is TUTMAN LLP, a limited liability partnership incorporated in England with registered number OC369415. The ACD is authorised and regulated by the Financial Conduct Authority (reference number 612721). Head Office and Registered Office of the ACD is the Exchange Building, St John's Street, Chichester, West Sussex PO19 1UP. This document constitutes a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000 and has been approved and issued by Stonehage Fleming Investment Management Limited. For details of the Funds investment policy, please see the Investment Objective and Policy section of the Fund Prospectus Document.

Before you invest you should read the Key Investor Information Document (KIID) and the Prospectus which contain detailed information. These documents are available in English, free of charge, upon request by writing to Thesis Unit Trust Management Limited at Exchange Building, St John's Street, Chichester, West Sussex PO19 1UP; or by phoning 01483 783 900 between 9am and 5pm Monday to Friday; or on the website at www.stonehagefleming.com/investments/funds. The distribution or possession of this document in jurisdictions outside the United

Kingdom may be restricted by law or other regulatory requirements. © Stonehage Fleming Investment Management Limited 2020

CONTACT FOR DEALING OR APPLICATION FORM ACD/Administrator: TUTMAN LLP t: 0333 300 0355

INVESTMENT MANAGER: Stonehage Heming Investment Management Limited, 15 Suffolk Street, London SW1Y 4HG United Kingdom e: enquiries@stonehagefleming.com Authorised and Regulated by the Financial Conduct Authority. Registered Company No. 4027720 England & Wales